---
title: "Nuvectis says China regulator approves ciprocopan for treatment-naive PNH patients"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/293607988.md"
description: "Nuvectis partner Haisco received China NMPA marketing approval for ciprocopan (NXP100) to treat treatment-naive paroxysmal nocturnal hemoglobinuria patients. Ciprocopan is the first once-daily oral complement Factor B inhibitor to achieve global approval. A separate application for previously treated PNH patients is currently under NMPA review."
datetime: "2026-07-23T11:32:19.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/293607988.md)
  - [en](https://longbridge.com/en/news/293607988.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/293607988.md)
---

# Nuvectis says China regulator approves ciprocopan for treatment-naive PNH patients

-   Nuvectis partner Haisco secured China NMPA marketing clearance for ciprocopan (NXP100) in treatment-naive paroxysmal nocturnal hemoglobinuria patients. \* Ciprocopan is the first once-daily oral complement Factor B inhibitor to win global approval. \* A separate China filing for PNH patients previously treated with anti-C5 therapies remains under NMPA review. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nuvectis Pharma Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607230730PRIMZONEFULLFEED9767018) on July 23, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [NVCT.US](https://longbridge.com/en/quote/NVCT.US.md)
- [002653.CN](https://longbridge.com/en/quote/002653.CN.md)

## Related News & Research

- [China's Haisco Gets China’s Nod for Rare Blood Disorder Drug](https://longbridge.com/en/news/293607538.md)
- [02:08 ETHaisco's Class 1 Innovative Drug Ciprocopan Succinate Tablets Approved in China, Offering a New Treatment Option for Patients With PNH](https://longbridge.com/en/news/293566351.md)
- [Adlai Nortye wins Australian HREC approval for AN4035 phase 1 trial](https://longbridge.com/en/news/294682603.md)
- [Final Approval Received for Emera’s Sale of New Mexico Gas Company | EMA Stock News](https://longbridge.com/en/news/294403864.md)
- [Dr. Reddy's registers PD-1 inhibitor in South Africa for recurrent or metastatic nasopharyngeal carcinoma](https://longbridge.com/en/news/294653513.md)